The OIG has issued its quarterly report comparing Medicare Part B drug average sales prices (ASPs) and AMPs, this one comparing second-quarter 2008 ASPs and AMPs and reviewing the impact on Medicare reimbursement for fourth quarter 2008. The OIG identified a total of 31 HCPCS codes with ASP that exceeded AMP by at least 5% in the second quarter of 2008. If reimbursement amounts for these 31 codes had been based on 103% of the AMPs, Medicare expenditures would have been reduced by $3.5 million during the fourth quarter of 2008. The OIG notes that it could not compare ASPs and AMPs for 68 drug codes because AMP data were not submitted; the OIG will continue to work with CMS to evaluate and pursue appropriate actions against manufacturers that fail to submit required data.